These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 26305886)

  • 1. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
    Kroiss M; Sbiera S; Kendl S; Kurlbaum M; Fassnacht M
    Horm Cancer; 2016 Dec; 7(5-6):345-355. PubMed ID: 27631436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways.
    Ruggiero C; Doghman-Bouguerra M; Ronco C; Benhida R; Rocchi S; Lalli E
    Mol Cell Endocrinol; 2018 Oct; 474():57-64. PubMed ID: 29474877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.
    Sbiera S; Kendl S; Weigand I; Sbiera I; Fassnacht M; Kroiss M
    Mol Cell Endocrinol; 2019 Jan; 480():36-41. PubMed ID: 30315857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells.
    Lin CW; Chang YH; Pu HF
    Toxicology; 2012 Aug; 298(1-3):14-23. PubMed ID: 22546480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
    van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
    Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
    Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
    Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
    Warde KM; Lim YJ; Ribes Martinez E; Beuschlein F; O'Shea P; Hantel C; Dennedy MC
    Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35797592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update in adrenocortical carcinoma.
    Fassnacht M; Kroiss M; Allolio B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer].
    Tkachuk AV; Beltsevich DG; Porubayeva EE; Urusova LS
    Probl Endokrinol (Mosk); 2023 Jan; 68(6):76-88. PubMed ID: 36689714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
    Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
    J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
    Smith DC; Kroiss M; Kebebew E; Habra MA; Chugh R; Schneider BJ; Fassnacht M; Jafarinasabian P; Ijzerman MM; Lin VH; Mohideen P; Naing A
    Invest New Drugs; 2020 Oct; 38(5):1421-1429. PubMed ID: 31984451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
    Lehmann TP; Wrzesiński T; Jagodziński PP
    Mol Med Rep; 2013 Mar; 7(3):893-900. PubMed ID: 23254310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
    Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
    Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
    Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V
    Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.